EU stop selling GVK test drug India or go to WTO

Source: Ding Xiangyuan 2015-04-17 if the EU does not reconsider the decision to suspend the sale of about 700 generic drugs, India may resort to the World Trade Organization (WTO) The CEO of GVK bioscience private limited said that the 700 generic drugs were approved based on clinical trials conducted by GVK The European Drug Administration (EMA) moratorium came into effect in January, a month after France, Germany, Belgium and Luxembourg suspended the sale of 25 generic drugs approved on the basis of tests conducted by GVK GVK is a privately held company, part of the GVK group, an Indian infrastructure builder, which conducts clinical research for pharmaceutical companies at home and abroad French media have been observing the production base of GVK bioscience company in southern India since last year, and found that the factory's ECG data fraud lasted for at least five years, and the regulatory authorities immediately took action on it French regulators immediately said the sale of the company's drug was suspended as a precaution and there was no reason to believe it was invalid or harmful The drugs suspended by EMA are from mylan and Abbott, as well as large Indian pharmaceutical companies, such as lupin and Dr redI laboratories Kantipudi, CEO of GVK Bioscience, told Reuters that after the company appealed, the Indian government set up a panel of experts to investigate the matter last year and found no fraud Kantipudi said an Indian government representative visited European authorities from February to march to ask for reconsideration of the decision to suspend sales India's commerce minister, kher, announced last week in the local daily newspaper that New Delhi is ready to take commercial and legal action, possibly through the WTO, if EMA is unable to do so The commerce department did not respond to a request for comment from Reuters "We have some legal options, but we will depend on the outcome of these diplomatic negotiations, and then we will decide with the Ministry of commerce what to do next," katipudi said He added that European authorities would visit the company for field observation, but had not yet announced the time EMA's press office did not immediately respond to a request for comment on the 15th GVK Bioscience is the latest Indian company to be internationally monitored for quality issues In the past two years, several large pharmaceutical companies in India have faced U.S and British sanctions for data fraud and health facilities.